CEO, Ray Therapeutics
Paul Bresge is Chief Executive Officer at Ray Therapeutics, an optogenetics gene therapy company for blinding diseases. Mr. Bresge was formerly the Chief Executive Officer at jCyte, where he played a critical role in the company since its inception. He brings more than 30 years of experience and a proven track record of success in creating shareholder value across a wide range of industries. He has led cross-functional teams to execute and close highly complex transactions, including jCyte’s $252M licensing deal with Santen Pharmaceutical in 2020. Mr. Bresge is very passionate about bringing therapies to patients, and he is pleased to support the Winning Pitch Challenge. He is very proud that in 2020, the company, Oculogenex, which he mentored, was the winner of the challenge.